datma.FED is a federated platform that enables health system labs to securely monetize their lab data while maintaining control and compliance over patient information. By providing pharmaceutical companies with access to standardized, ready-to-use datasets, datma.FED addresses the challenge of incomplete data in drug discovery and development.
Funding
$6.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GVFounders
Product
Problem
Health system labs generate vast amounts of valuable data that often remain underutilized. These labs face challenges in monetizing their data due to difficulties in standardization, compliance, and establishing connections with pharmaceutical companies. This results in missed revenue opportunities and hinders the advancement of drug discovery and development.
Solution
datma.FED is a federated platform that enables health system labs to securely monetize their lab data while maintaining complete control and compliance. The platform organizes and standardizes lab data, making it readily accessible to pharmaceutical companies seeking real-world data for research and development. Identifiable patient-level data never leaves the lab's infrastructure, ensuring data privacy and adherence to regulations. datma.FED proactively connects labs with data consumers, facilitating a symbiotic relationship where both parties benefit from shared data access and revenue generation.
Target Audience
The primary customers are health system labs and reference labs seeking to monetize their underutilized data, as well as pharmaceutical companies and researchers looking to supplement existing datasets with real-world lab data.
Features
- Federated architecture ensures patient-level data remains within the lab's infrastructure, maintaining control and compliance.
- Data organization and standardization processes prepare lab data for immediate use by pharmaceutical companies.
- Customizable privacy settings allow labs to tailor data access controls to their specific needs.
- Shared-upside revenue model generates consistent revenue for labs as the network of data consumers expands.
- Proactive business development resources connect labs with pharmaceutical companies, eliminating the need for outreach efforts.